Review top news and interview highlights from the week ending October 7, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
The new, 2-year data is from a roll-in cohort of 10 patients presented at the HFSA 2022 meeting.
Five patients with lupus treated with anti-CD19 CAR T-cell therapy are now in remission.
The chief executive officer of Cytoimmune discussed the company’s technology platforms and programs.
A prior resubmission in June 2022 was delayed with requests for additional durability and safety data.
The director of translational research in myeloma at the Tisch Cancer Institute discussed investigating sequential T cell redirection therapies.